CNO Financial Group, Inc. extended its Section 382 Rights Agreement through November 13, 2029 and updated the purchase price. The agreement is expected to be submitted for shareholder approval at the 2027 annual meeting.
CNO · CNO Financial Group, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
CNO reported third-quarter net operating income of $179.1 million, up from $127.2 million, while insurance product margin rose to $333.0 million from $300.5 million.
CNO reported third-quarter operating earnings per diluted share up 47% and raised 2026 operating earnings per share guidance to $5.05 to $5.15. A $270 million reserve cession to its Bermuda affiliate took effect October 1st.
CNO Financial Group reported third-quarter 2026 net income of $161 million and operating EPS growth of 47%, raised 2026 operating EPS guidance with its midpoint up 9%, and reinsured approximately $270 million of Colonial Penn life statutory reserves.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Oct 30, 2026TL;DR. CNO delivered strong earnings, sales, margin, investment-income and ROE growth and raised full-year operating EPS guidance. Key offsets included higher Medicare Supplement morbidity, lower consumer NAP and fee income, nonrecurring investment-income outperformance, higher TechMod expense and larger realized investment losses.
- + Full-year operating EPS guidance was raised, with the midpoint up 9% from prior guidance.
- + Operating EPS increased 47% in the quarter and 43% year to date.
- + CNO delivered a 17th consecutive quarter of sales growth and a 15th consecutive quarter of producing agent growth.
- + Total insurance product margin excluding significant items increased 7%.
- + Total net investment income increased 13% year over year, marking a 12th consecutive quarter of growth.
- + Trailing 12-month operating ROE was 15.4%, or 14.1% excluding significant items.
- − Medicare supplement results reflected higher morbidity, partly offset by block growth and rate increases.
- − Total consumer life and health NAP declined year over year against a strong comparison.
- − Fee income declined 72% year over year to $(1.1) million.
- − Favorable alternative investment income contributed approximately $12 million above the long-term yield estimate, but management did not expect that contribution to continue.
- − TechMod expense increased to $10.1 million in 3Q26 from $7.2 million in 3Q25.
- − Net realized investment losses increased to $48.3 million from $8.8 million.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Collected premiums from annuity and interest-sensitive life products | $603.3M | the second quarter of 2026 filing | — |
| Interest margin/average net insurance liabilities | 0.1% | the second quarter of 2026 filing | — |
| Margin excluding advertising expense/insurance policy income | 34% | the second quarter of 2026 filing | — |
| Margin from interest-sensitive life | $26.4M | the second quarter of 2026 filing | — |
| Margin from long-term care | $40.6M | the second quarter of 2026 filing | — |
| Margin from Medicare supplement | $36.5M | the second quarter of 2026 filing | — |
| Margin from supplemental health | $70.1M | the second quarter of 2026 filing | — |
| Margin from traditional life | $44.8M | the second quarter of 2026 filing | — |
| Total health margin | $147.2M | the second quarter of 2026 filing | — |
| Total health margin margin/insurance policy income | 34% | the second quarter of 2026 filing | — |
| Total investment income not allocated to product lines | $49.4M | the second quarter of 2026 filing | — |
| Total life margin | $71.2M | the second quarter of 2026 filing | — |
| Underwriting margin | $26.1M | the second quarter of 2026 filing | — |
| Underwriting margin/insurance policy income | 52% | the second quarter of 2026 filing | — |
| Annuity Account Values | $13.71B | 2Q26 | — |
| Annuity Collected Premiums | $536M | 2Q26 | — |
| Annuity margin non-GAAP | $60.6M | 2Q 2026 | — |
| associates | 3,200 | As of 2026 | — |
| Average Book Value of Investments & Cash | $32.71B | 2Q26 | — |
| average cost per repurchased share | $46.57 | 2Q26 | — |
| Average Yield on Allocated Investments | 4.91% | 2Q26 | — |
| Book value per common share, excluding accumulated other comprehensive loss non-GAAP | $40.72 | Jun-26 | — |
| Book Value per Diluted Share x AOCI non-GAAP | $39.92 | 2Q26 | — |
| Book value per diluted share, excluding accumulated other comprehensive income (loss) non-GAAP | $39.92 | As of June 30, 2026 | — |
| Client Assets in BD and Advisory non-GAAP | $5.69B | 2Q26 | — |
| Client Assets in Brokerage and Advisory at end of period | $5.69B | 2Q26 | — |
| common shares outstanding | 92.7M | As of June 30, 2026 | — |
| common shares repurchased | 1.3M | 2Q26 | — |
| common stock repurchased | $60M | 2Q26 | — |
| company dividends paid to the holding company | $20M | 2Q26 | — |
| Consolidated capital, excluding accumulated other comprehensive income (loss) and net operating non-GAAP | $3.5B | 2Q26 trailing four quarter average | — |
| consolidated statutory risk-based capital ratio non-GAAP | 377% | Q2 2026 | — |
| Debt to Capital excluding $500 million note that matured May 2025 non-GAAP | 26.1% | 2Q26 | — |
| debt-to-total capital ratio, excluding accumulated other comprehensive income (loss) non-GAAP | 26.1% | As of June 30, 2026 | — |
| dividends paid on common stock | $16.8M | 2Q26 | — |
| Earned yield | 4.88% | 2Q26 | — |
| estimated statutory operating gain non-GAAP | $35.4M | 2Q26 | — |
| exclusive agents | 5,100 | As of 2026 | — |
| Expense Ratio non-GAAP | 18.4% | 2Q26 | — |
| Expense Ratio - YTD non-GAAP | 18.7% | 2Q26 YTD | — |
| Free Cash Flow non-GAAP | $30.7M | 2Q26 | — |
| Health margin non-GAAP | $147.2M | 2Q 2026 | — |
| Insurance Product Margin Excluding Significant Items - Annuity non-GAAP | $60.6M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Fixed Indexed Annuities non-GAAP | $49.2M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Fixed Interest Annuities non-GAAP | $7.8M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Health non-GAAP | $147.2M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Interest Sensitive Life non-GAAP | $26.4M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Life non-GAAP | $71.2M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Long-term Care non-GAAP | $40.6M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Medicare Supplement non-GAAP | $36.5M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Other Annuities non-GAAP | $3.6M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Supplemental Health non-GAAP | $70.1M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Total Margin non-GAAP | $279M | 2Q26 | — |
| Insurance Product Margin Excluding Significant Items - Traditional Life non-GAAP | $44.8M | 2Q26 | — |
| Invested Assets | $32B | as of 6/30/2026 | — |
| Life margin non-GAAP | $71.2M | 2Q 2026 | — |
| Margin from fixed indexed annuities non-GAAP | $49.2M | 2Q 2026 | — |
| Margin/average net insurance liabilities non-GAAP | 1.74% | 2Q 2026 | — |
| Net operating income non-GAAP | $491.4M | Trailing four quarters ended 2Q26 | — |
GAAP → non-GAAP reconciliationGAAP Net income applicable to common stock $125.9M
+$13.6M Net realized investment (gains) losses from sales and impairments
+$1.1M Net change in market value of investments recognized in earnings
+$0M Fair value changes related to the agent deferred compensation plan
-$34.6M Changes in fair value of embedded derivative liabilities and market risk benefits
+$9.7M Expenses related to TechMod initiative
+$0M Goodwill and intangible asset impairment
+$1.1M Net loss related to divested business
+$0.4M Other
+$2.3M Income tax expense (benefit) on non-operating income
= Net operating income $119.5M
|
|||
| Net operating income excluding significant items non-GAAP | $119.5M | 2Q26 | — |
| New Annualized Premiums non-GAAP | $127.7M | 2Q26 | — |
| New Money Rate | 6.16% | 2Q26 | — |
| Operating return on equity, excluding significant items non-GAAP | 13.1% | Trailing four quarters ended June 30, 2026 | — |
| policies | 3.3M | As of 2026 | — |
| Policyholder and Client Assets | $19.4B | 2Q26 | — |
| Pre-tax operating earnings non-GAAP | $617.2M | Trailing four quarters ended 2Q26 | — |
| Producing Agent Counts (PAC) non-GAAP | 5,125 | 2Q26 | — |
| remaining repurchase authority | $300.4M | As of June 30, 2026 | — |
| Rolling Twelve Months Expense Ratio non-GAAP | 18.5% | 2Q26 TTM | — |
| Total insurance product margin non-GAAP | $279M | 2Q 2026 | — |
| Total Margin | $279M | 2Q26 | — |
| Total Net Investment Income non-GAAP | $327.5M | 2Q26 | — |
| TTM operating ROE excluding significant items non-GAAP | 13.1% | 2Q26 | — |
| unrestricted cash and investments held by holding company | $233.2M | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Insurance - Life — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNO
this stock
CNO Financial Group, Inc.
|
$5.17B | +33.2% | +0.9% | 12.9 | 2.8% |
|
CILJF
China Life Insurance Co Ltd
|
$81.12B | -16.8% | — | — | 0.0% |
|
MFC
Manulife Financial Corp
|
$72.39B | +20.8% | — | — | 0.8% |
|
MET
Metlife Inc
|
$63.79B | +28.6% | +8.6% | 13.2 | 1.7% |
|
AFL
Aflac Inc
|
$63.16B | +15.8% | -9.3% | 18.8 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 17
CNO Financial Group, Inc. extended its Section 382 Rights Agreement through November 13, 2029 and updated the purchase price. The agreement is expected to be submitted for shareholder approval at the 2027 annual meeting.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNO | -2.1% | +3.1% | +22.4% | -1.9% | +33.2% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +0.3% | +7.9% | +25.4% | +1.2% | +25.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.